Ulcerative Colitis
📧 Sign up to get email alerts when something new happens for Ulcerative Colitis.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2024-08-22FDA Approved: MESALAMINE — Original Application (Teva Pharmaceuticals, Inc.)
FDA approved mesalamine under an Original Application (ANDA) for Teva Pharmaceuticals, enabling marketing of a generic mesalamine product.
-
CLINICAL_TRIALS research · 2024-08-22Clinical Trial Update: A Post-Marketing Surveillance Study to Assess Safety of Ozanimod in Patients With Moderate to Severe Active UC in Korea
This document reports an ongoing post-marketing surveillance study in Korea to evaluate the safety of Ozanimod for adults with moderate to s…
-
CLINICAL_TRIALS research · 2024-08-22Clinical Trial Update: Safety and Efficacy of Fecal Microbiota Transplantation [NA]
A multicondition clinical trial evaluating fecal microbiota transplantation for various conditions; the study is currently recruiting.
-
CLINICAL_TRIALS research · 2024-08-12Clinical Trial Update: Longitudinal Study on Bacterial Production of LPC and LPA in Patients With Inflammatory Bowel Disease
A longitudinal clinical trial studying bacterial production of lysophosphatidylcholine (LPC) and lysophosphatidic acid (LPA) in patients wit…
-
CLINICAL_TRIALS trial_result · 2024-08-06Clinical Trial Update: A Study on How Vedolizumab is Given and the Outcomes for Adults With Inflammatory Bowel Disease (VARIETY-Belgium)
A completed study assessing how vedolizumab is administered and the outcomes in adults with inflammatory bowel disease (VARIETY-Belgium).
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2024-07-31Clinical Trial Update: Pharmacokinetics, Efficacy and Safety of CT-P13 Subcutaneous as Induction Therapy in Patients With Active CD or UC [Phase 3]
Phase 3 clinical trial evaluating pharmacokinetics, efficacy and safety of subcutaneous CT-P13 as induction therapy in adults with active Cr…
-
FDA approval · 2024-07-30FDA Approved: MESALAMINE — Supplemental Application (ANI Pharmaceuticals, Inc.)
The FDA approved a supplemental application for MESALAMINE from ANI Pharmaceuticals, Inc.
-
FDA approval · 2024-07-30FDA Approved: DIPENTUM — Supplemental Application (Viatris Specialty LLC)
The FDA approved a supplemental application for Dipentum (olsalazine sodium) submitted by Viatris Specialty LLC.
-
FDA label_change · 2024-07-30FDA Approved: PENTASA — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
FDA approved a supplemental application for Pentasa (mesalamine) from Takeda Pharmaceuticals America, Inc., updating the product labeling.
-
CLINICAL_TRIALS trial_result · 2024-07-30Clinical Trial Update: Comparison of Two Different Golimumab Dosing Regimens for Ulcerative Colitis [Phase 4]
Phase 4 clinical trial comparing two golimumab dosing regimens for ulcerative colitis has completed.
-
CLINICAL_TRIALS research · 2024-07-29Clinical Trial Update: Clinical Study to Evaluate the Possible Efficacy and Safety of Febuxostat in Patients With Ulcerative Colitis Treated With Mesalamine [EARLY_Phase 1]
A Phase 1 study investigating the potential efficacy and safety of febuxostat in patients with ulcerative colitis treated with mesalamine; c…
-
CLINICAL_TRIALS research · 2024-07-26Clinical Trial Update: Subcutaneous Infliximab After A Previous Intravenous Dose Optimization [Phase 4]
Phase 4 trial update evaluating subcutaneous infliximab after previous intravenous dose optimization for inflammatory bowel diseases, includ…
-
CLINICAL_TRIALS trial_result · 2024-07-22Clinical Trial Update: A Study of Vedolizumab in Adults in Real-World Practice
This real-world study of Vedolizumab in adults with ulcerative colitis or Crohn's disease has completed. It evaluated treatment outcomes in …
-
CLINICAL_TRIALS research · 2024-07-19Clinical Trial Update: The Role of Gut Bacteria in the Immune Response to Vaccination in Patients With Ulcerative Colitis [NA]
This clinical trial update describes a study assessing how gut bacteria influence the immune response to vaccination in patients with ulcera…
-
CLINICAL_TRIALS trial_result · 2024-07-12Clinical Trial Update: A Study of the Safety, Efficacy, and Biomarker Response of BMS-986165 in Participants With Moderate to Severe Ulcerative Colitis [Phase 2]
Phase 2 study evaluating the safety, efficacy, and biomarker response of BMS-986165 in adults with moderate to severe ulcerative colitis has…
-
CLINICAL_TRIALS research · 2024-07-11Clinical Trial Update: IBD Registry in a Sub-Saharan African Population
A Sub-Saharan Africa inflammatory bowel disease registry is recruiting participants at the University of Zimbabwe, focusing on ulcerative co…
-
CLINICAL_TRIALS research · 2024-07-11Clinical Trial Update: Transperineal Ultrasound for Assessing and Predicting Response in Hospitalized Patients with a Flare of Ulcerative Colitis
This clinical trial is evaluating transperineal ultrasound to assess and predict response in hospitalized patients with a flare of ulcerativ…
-
CLINICAL_TRIALS research · 2024-07-10Clinical Trial Update: Comparison Between Chromoendoscopy and Virtual Chromoendoscopy (NBI, I-scan, FICE) for Detection of Neoplasia in Long Standing Ulcerative Colitis [NA]
This clinical trial compares chromoendoscopy to virtual chromoendoscopy (NBI, I-scan, FICE) for detecting neoplasia in long-standing ulcerat…
-
FDA approval · 2024-07-09FDA Approved: MERCAPTOPURINE — Supplemental Application (Nova Laboratories, Ltd)
The FDA approved a supplemental application for mercaptopurine (Purixan) by Nova Laboratories, Ltd., updating the product labeling and/or in…
-
FDA approval · 2024-07-09FDA Approved: MERCAPTOPURINE — Supplemental Application (Florida Pharmaceutical Products, LLC)
FDA approved a supplemental application for Mercaptopurine submitted by Florida Pharmaceutical Products, LLC.
-
CLINICAL_TRIALS trial_result · 2024-07-03Clinical Trial Update: BI 655130 Long-term Treatment in Patients With moderate-to Severe Ulcerative Colitis [Phase 2]
This is a Phase 2 long-term treatment trial of BI 655130 for adults with moderate-to-severe ulcerative colitis that has completed. Results w…
-
CLINICAL_TRIALS research · 2024-07-03Clinical Trial Update: Combined Application of EEN in the Induction of Remission in PUC [Phase 4]
A Phase 4 clinical trial is evaluating the use of Exclusive Enteral Nutrition to induce remission in pediatric ulcerative colitis and is cur…
-
CLINICAL_TRIALS research · 2024-07-03Clinical Trial Update: Spatially Resolved IBD: Spatial Transcriptomics of Inflammatory Bowel Disease (IBD)
This clinical trial registered by IRCCS San Raffaele investigates spatial transcriptomics in inflammatory bowel disease and is set to enroll…
-
CLINICAL_TRIALS trial_result · 2024-07-01Clinical Trial Update: A Study to Evaluate the Effect of Intravenous (IV) Infusions of Risankizumab on Pharmacokinetics of Cytochome P450 Substrates in Adult Participants With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease [Phase 1]
A Phase 1 study assessing whether intravenous risankizumab alters the pharmacokinetics of cytochrome P450 substrates in adults with moderate…
-
FDA approval · 2024-06-28FDA Approved: USTEKINUMAB-TTWE — Original Application (Quallent Pharmaceuticals Health LLC)
FDA approves a new biologic product, ustekinumab-tTWE, from Quallent Pharmaceuticals Health LLC, via an Original Biologics License Applicati…